Washington, D.C., partner, Jesse Witten, will be a panel member at the Pharmaceutical Compliance: Off-Label Drug Promotion conference in Philadelphia on November 9. The panel, entitled “Managing Risk for Products with High Off-Label Use,” will discuss compliance risks and safeguards that pharmaceutical companies should consider for products that have high levels of off-label prescription by physicians, such as oncology and psychiatric drugs.
Source: Q1 Productions’ Pharmaceutical Compliance: Off-Label Drug Promotion Conference